RenovoRx (RNXT) Q3 2026 Earnings Call Transcript

RenovoRx (RNXT) reported Q3 2026 earnings, highlighting growth in active commercial cancer centers (26 up from 21) and a robust commercial funnel. The company expects to meet its year-end target of 36 active centers. Revenue guidance remains $3.75M-$4.25M. New account activations and repeat orders are key growth metrics. RenovoCath's use expanded to sarcoma and a neoadjuvant trial, with 10 issued U.S. patents and more pending.

Original reporting
Published Nov 6, 2026, 5:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RenovoRx (RNXT) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$RNXTBullishMed
01

Why it matters

The key tradable items are operating KPIs (active commercial centers, commercial funnel size, repeat ordering) and the reaffirmed full-year 2026 revenue guidance range, which together inform expectations for near-term execution.

02

Market read

Investors can update positioning based on management’s stated activation pace, funnel expansion, and reaffirmed revenue guidance for 2026.

03

What to watch

The transcript emphasizes activations and repeat orders but provides limited detail on unit economics, reimbursement dynamics, or competitive landscape that could affect sustainability of growth.

Relevance 6/10Novelty 6/10Timing: during/after the Q3 2026 earnings call transcript release

Background

The article is a transcript of RenovoRx’s Q3 2026 earnings call, focused on commercialization of RenovoCath/TAMP for pancreatic cancer and expansion into other solid tumors.

Company-level read

Ticker impact

$RNXTBullishMedium confidence
Context

RenovoRx reports Q3 2026 call metrics, including active commercial cancer center customers rising 21 to 26 and maintaining 2026 revenue guidance of $3.75M to $4.25M.

Expected impact

Likely upward bias as investors price in continued commercial activation momentum and guidance reaffirmation.

Evidence & confidence

The transcript provides specific operating KPIs and a reiterated revenue range, which can drive sentiment and positioning ahead of subsequent updates.

Market effects

Reinforces investor interest in localized drug delivery platforms for interventional oncology, potentially improving sentiment toward similar device-enabled oncology approaches.

No clear regional read-through beyond U.S. cancer-center commercialization.

Limited direct global impact; discussion is primarily U.S. commercial adoption and U.S. patent activity.

Counterpoint

Commercial progress may still be early relative to the addressable market, and guidance is a narrow range that could be sensitive to activation pace.

Key entities

  • RenovoRx

    Subject of the earnings call transcript; reports active commercial center growth, commercial funnel expansion, IP updates, and reiterates 2026 revenue guidance.

  • RenovoCath

    Device enabling TAMP localized drug delivery; discussed as driving account activations and repeat orders.

  • TIGeR-PaC trial

    Phase III trial for locally advanced pancreatic cancer evaluating targeted delivery of gemcitabine versus systemic gemcitabine plus Abraxane.

Related articles

$RNXTMed

RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding

RenovoRx Inc (RNXT) reported Q3 2026 record revenue of $1.07M, up 17% sequentially. CEO Sean Bagai discussed potential impacts of Razin-Q approval on pancreatic cancer treatment and commercialization plans. The company has 26 active commercial centers, with a target of 36 by year-end. Phase III TIGER-PACT trial data is expected in H2 2027. Gross margin was 82%, and cash position is $10.4M. Full-year 2026 revenue guidance remains $3.75M-$4.25M.

$RNXTMed

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel…

RenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion

$RNXTMedAI 8/10

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

$RNXTMedAI 8/10

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.